Skip to main
  1. Stocks
  2. Rein Therapeutics Inc
  3. Forecast
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics is attractive fundamentally because LTI-03 has a differentiated Caveolin-1-based mechanism that aims to both suppress profibrotic signaling and preserve alveolar epithelial cells, a profile that could offer more than existing antifibrotics in IPF. The investment case has also strengthened materially as the $57.5M financing removed the near-term funding overhang, with $43.6M in cash, cash equivalents and marketable securities at 2Q26 and expected runway into 1Q28, allowing the market to focus on execution rather than dilution risk. With RENEW already above 25% enrollment, all five planned countries enrolling, and initial/interim data expected in 2H26, the stock now has a credible near-term catalyst to test whether promising Phase 1b biomarker activity can translate into clinically meaningful benefit.

Bears say

Rein Therapeutics is viewed negatively because its valuation depends heavily on an early-stage LTI-03 program assigned only a 30% probability of success, reflecting prior setbacks in idiopathic pulmonary fibrosis, while the company still needs to extend its limited cash runway to finish the ongoing Phase 2 trial. The DCF framework also embeds caution through a 14.1% WACC, a 4.0x exit multiple to 2036 estimates, and a -8.7% terminal growth rate, signaling muted long-term confidence and constrained upside assumptions. Additional concerns include 57.5M new shares from the recent raise, financing and regulatory risk, competition before LTI-03 launch, and the stock trading near $1, which creates bid compliance risk.

RNTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

RNTX Analyst Forecast & Price Prediction

Get the latest RNTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, RNTX has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


RNTX Analyst Forecast & Price Prediction

Get the latest RNTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RNTX stock data and trends